Rajiv Sarman Shukla
Chief Executive Officer at CARMELL CORPORATION
Net worth: 7 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Laura Niklason | M | 61 | 20 years | |
| David Anderson | M | 71 | - | |
| Charles Green | M | 68 | 2 years | |
| Emery Brown | M | 67 | 3 years | |
| Kathleen Sebelius | F | 75 | 3 years | |
| Scott Frisch | M | - | 1 years | |
| Diane Seimetz | M | 53 | 2 years | |
| Michael Constantino | M | 61 | 3 years | |
| Todd Pope | M | 58 | 3 years | |
| Max Wallace | M | 72 | 3 years | |
| Susan Windham-Bannister | M | 74 | 3 years | |
| Kathryn Gregory | F | 62 | - | |
| Gordon Binder | M | 88 | 3 years | |
| Brian Levy | M | 72 |
InflammX Therapeutics, Inc.
 InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Richard Upton | M | 60 | - | |
| Colin Richard Green | M | 80 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Gilles Spenlehauer | M | - | 1 years | |
| Dale Sander | M | 64 | 3 years | |
| David Alan Pool | M | - |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Richard Rubino | M | 66 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Sabrina Osborne | F | - | - | |
| Bryan Cassaday | M | 56 | 1 years | |
| Yang Cao | M | 58 | 2 years | |
| Brady Dougan | M | 64 | 3 years | |
| David Boyer | M | - |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Shamik Parikh | M | 51 | 2 years | |
| William Scheessele | M | 53 | 3 years | |
| Mike McDermott | M | 58 | 21 years | |
| James Blair | M | 84 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Phil Rosenfeld | M | - |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Jason Werner | M | 46 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
| Heather Prichard | M | 46 | 3 years | |
| Suneet Varma | M | 55 | 23 years | |
| Patrick Sturgeon | M | 47 | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Kindler | M | 68 | 8 years | |
| Alexander John Joseph | M | 85 |
Constellation Alpha Capital Corp.
 Constellation Alpha Capital Corp. Financial ConglomeratesFinance Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL. | 2 years |
| Craig Pollak | M | 53 |
Constellation Alpha Capital Corp.
Constellation Alpha Capital Corp. Financial ConglomeratesFinance Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL. | - |
| Richard Rosling | M | 61 |
Constellation Alpha Capital Corp.
Constellation Alpha Capital Corp. Financial ConglomeratesFinance Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL. | - |
| Kewal Kundanlal Handa | M | 71 |
Constellation Alpha Capital Corp.
Constellation Alpha Capital Corp. Financial ConglomeratesFinance Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL. | - |
| Paul Fitzhenry | M | 63 | 4 years | |
| David Paul Rasquinha | M | 59 | 3 years | |
| Venkiteswaran Subramaniam | M | 83 | 6 years | |
| Everett Cunningham | M | 57 | 9 years | |
| Jeffrey Lawson | M | 60 | - | |
| Yi Ning Zhao | M | 53 | 8 years | |
| Alexandra Kropotova | M | 51 | 5 years | |
| Nils Peter Sandehed | M | 72 | 1 years | |
| George Milne | M | 80 | 32 years | |
| Padmaja Bhaskaran | F | - | 3 years | |
| Ajay Kumar Parduman Sharma | M | 61 | 1 years | |
| Comal Ramachandran Gayathri | F | 75 | 4 years | |
| Jacob M. Plotsker | M | 56 | 16 years | |
| Michael R. Jirousek | M | 65 | 5 years | |
| Viviane Monges | F | 60 | 5 years | |
| Mark J. Bamberger | M | 71 | 4 years | |
| Michael Bruce | M | - | 12 years | |
| Dario Paggiarino | M | 67 | 10 years | |
| Catherine Knupp | M | 63 | - | |
| Mark White | M | 68 | 12 years | |
| William S. Korinek | M | - | 9 years | |
| Nenad Sarapa | M | - | 6 years | |
| Feng Guo | M | 54 | 11 years | |
| John Chapman | M | 70 | 4 years | |
| Matthew Rossen | M | 47 | 9 years | |
| Jeffrey Kent | M | 62 | 4 years | |
| Spiros Liras | M | - | 4 years | |
| Deborah Baron | F | 55 | - | |
| Margaret Marshall | M | 67 | 8 years | |
| Mark J. Taisey | M | - | 5 years | |
| Adrian Otte | M | - | 6 years | |
| Tanya de Foras | F | 53 | 10 years | |
| Christopher Verni | M | 49 | 3 years | |
| Charles Baum | M | 65 | 9 years | |
| Edmund Harrigan | M | 71 | 12 years | |
| Ravi Kiron | M | 64 | 13 years | |
| Frank Sciavolino | M | 83 | 35 years | |
| John W. Poyhonen | M | 64 | 7 years | |
| Robert E. Grasty | M | 55 | - | |
| Lance Berman | M | 53 | 6 years | |
| Kenneth Bahrt | M | 71 | 4 years | |
| John F. Niblack | M | 85 | 35 years | |
| Jean-Paul Vallès | M | - | 25 years | |
| William Sigmund | M | - | 4 years | |
| Linda Armstrong | M | 61 | 6 years | |
| Wesley W. Day | M | 59 | 12 years | |
| Warren R. Winter | M | - | 15 years | |
| Julie A. Olson | M | - | 19 years | |
| Antony Loebel | M | 64 | 1 years | |
| George W. Evans | M | 70 | 26 years | |
| Tim Bertram | M | 68 | 5 years | |
| Charles McWherter | M | 69 | 4 years | |
| Nicholas Lee Gurreri | M | - | 4 years | |
| Thomas G. Gant | M | - | 6 years | |
| Andreas Fibig | M | 62 | 2 years | |
| Scott Cheshareck | M | - | 16 years | |
| Dan Garofalo | M | 48 | 4 years | |
| Krishan K. Arora | M | 83 | 5 years | |
| Daniel Cronin | M | 78 | - | |
| Barbara Wirostko | M | 58 | 4 years | |
| Seth Brodsky | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 90 | 90.00% |
| India | 7 | 7.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Rajiv Sarman Shukla
- Personal Network
